Реестр препаратов-кандидатов для лечения и профилактики COVID-19
Bevacizumab is an anti VEGF recombinant humanized monoclonal antibody, which has been used in anti-tumor treatment for 16 years. Approved to treat certain types of cancer.
Vazegepant is a Calcitonin gene-related peptide (CGRP) receptor antagonist that may potentially blunt the severe inflammatory response at the alveolar level, delaying or reversing the path towards oxygen desaturation in patients with COVID-19.
Bifidobacteria monovalent SARS-CoV-2 DNA oral vaccine for prevention of COVID-19.
Each oral dose of bacTRL-Spike contains bacterial medium with either 1 billion (Group 1A), 3 billion (Group 2A) or 10 billion (Group 3A) colony-forming-units of live Bifidobacterium longum, which has been engineered to deliver plasmids containing synthetic DNA encoding spike protein from SARS-CoV-2.
Bacille Calmette-Guérin (BCG) is a vaccine against tuberculosis, with protective non-specific effects against other respiratory tract infections in in vitro and in vivo studies, and reported morbidity and mortality reductions as high as 70%.
mRNA-based vaccine targeting infectious disease pathogens.
The Covid-19/aAPC vaccine is prepared by applying lentivirus modification including immune modulatory genes and the viral minigenes, to the artificial antigen presenting cells (aAPCs).
V-SMENP-DC vaccine is made by modifying DC with lentivirus vectors expressing Covid-19 minigene SMENP and immune modulatory genes. CTLs will be activated by LV-DC presenting Covid-19 specific antigens.